Accustem Sciences Stock EBITDA
| ACUT Stock | USD 0.36 0.03 9.09% |
Accustem Sciences fundamentals help investors to digest information that contributes to Accustem Sciences' financial success or failures. It also enables traders to predict the movement of Accustem OTC Stock. The fundamental analysis module provides a way to measure Accustem Sciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Accustem Sciences otc stock.
Accustem |
Accustem Sciences OTC Stock EBITDA Analysis
Accustem Sciences' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Accustem Sciences reported earnings before interest,tax, depreciation and amortization of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The ebitda for all United States stocks is 100.0% higher than that of the company.
Accustem EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Accustem Sciences' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Accustem Sciences could also be used in its relative valuation, which is a method of valuing Accustem Sciences by comparing valuation metrics of similar companies.Accustem Sciences is currently under evaluation in ebitda category among its peers.
Accustem Fundamentals
| Shares Owned By Insiders | 45.00 % |
About Accustem Sciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Accustem Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Accustem Sciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Accustem Sciences based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Accustem OTC Stock Analysis
When running Accustem Sciences' price analysis, check to measure Accustem Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accustem Sciences is operating at the current time. Most of Accustem Sciences' value examination focuses on studying past and present price action to predict the probability of Accustem Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accustem Sciences' price. Additionally, you may evaluate how the addition of Accustem Sciences to your portfolios can decrease your overall portfolio volatility.